Alembic sees India sales recovering from Q1FY21, expects 10-12% growth

This financial year should see 15-20 product launches in the US

After nearly flat domestic sales growth in the December quarter, Alembic Pharmaceuticals says it expects 10-12 per cent growth from the April-June quarter. 

“The first hint of it will be seen in the March (ongoing) quarter, though domestic sales (growth) would be roughly flat this (financial) year,” R K Baheti CFO, said. Its financial results for Q3 showed the US business grew a little over 60 per cent. India sales growth was barely 1 per cent. It needs the latter to grow, at a time when it expects more competition for the US business. 

Domestic sales were hit after the company stopped